Promising results for Swedish cancer drug candidate
A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet, Sweden presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.The journal Blood has published a new study on a drug candidate